Topic summary

Revisiting: Melanocortin agonists: mechanism and the documented adverse profile

Compounds › Other compounds custom synthesis mislabelling research use only Solved

This is a generated summary. It shows the 9 most-liked posts from a topic of 142, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

a.vestergaardTL2 Solution19 Sep 2024#8

Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a solubility profile and the supplier should state it.

A single observation, in a thread that deserves better than single observations.

17 likes 22mo

f.sjobergTL225 Sep 2024 · edited#17

n.nyberg, post #12: Counterpoint on Melanocortin agonists, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out. Go to post

Where I part company with post #15, and it is a narrow parting.

A note on how Melanocortin agonists gets discussed rather than on Melanocortin agonists itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.

29 likes in reply to #12 22mo

k.salinasTL212 Oct 2024#46

c.cardoso, post #18: Post #17 is the version of this I will quote in future. One addition. Melanocortin agonists came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction. Go to post

Melanotan II is a non-selective melanocortin agonist, which is why its effects are not confined to pigmentation. The non-selectivity is the mechanism and not a side issue.

Not the answer, but possibly the question that gets there.

28 likes in reply to #18 22mo

c.amankwahTL218 Oct 2024#58

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

26 likes 21mo

t.steenkampTL2Member21 Oct 2024#63

a.teixeira, post #2: Everything in the opening post holds. The case it does not cover is the one I have. Melanotan II is a non-selective melanocortin agonist, which is why its effects are not confined to pigmentation. The non-selectivity is the mechanism and not a side issue. I checked the source rather than the summary, and they differ. Go to post

Picking up post #62: that is the part I would want checked first.

Where I have landed on Melanocortin agonists, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it from somewhere that did not measure it.

27 likes in reply to #2 21mo

buffer_reviewTL3Regular31 Oct 2024#84

Bookmarking this. I will come back when I have something worth adding.

27 likes in reply to #2 21mo

r.ekstromTL28 Nov 2024#101

Worth separating two things that post #98 runs together.

Adding a reference point for Melanocortin agonists. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.

30 likes 21mo

ppm_errorTL3Analytical chemist18 Nov 2024#124

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

29 likes 20mo

r.friskTL223 Nov 2024#136

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

31 likes 20mo

Read the full topic (142 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Compounds this community declines to help with, and why — does this still hold? Compounds › Other compounds custom synthesis research use only mislabelling Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first post,…	+3	7	26k	7h
How to research a compound with no human data without deceiving yourself Compounds › Other compounds needs a source mislabelling custom synthesis research use only Solved Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Question about what the published evidence for this compound actually…	+107	119	11k	12mo
Research-use-only status: what it means legally and practically — a second dataset Compounds › Other compounds research use only mislabelling needs a source custom synthesis Solved Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Research-use-only status. It…	+109	125	2k	16mo
AOD-9604 and the fragment hypothesis, revisited Compounds › Other compounds mislabelling research use only custom synthesis needs a source Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Reading back through what has been written here about AOD-9604, three…	+40	44	2.8k	6mo
Compounds this community declines to help with, and why Compounds › Other compounds research use only needs a source mislabelling custom synthesis Solved Wiki Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a compound without…	+81	87	35k	10mo

Related topics — sharing the tags custom synthesis, mislabelling, research use only

Topic	Participants	Replies	Views	Activity
Reading a regulatory notice rather than an article about it — what changed since Sourcing › Regulatory research use only MHRA FDA personal import Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since…	+28	32	640	13mo
Prescription requirements and telehealth models — a second dataset Sourcing › Regulatory compounding EMA MHRA personal import On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth…	+87	94	1.1k	21d
Why this community will not facilitate a group purchase Sourcing › Payments documentation quality payments research use only Asking directly, because I could not find a straight answer: Why this community will not facilitate a group purchase Currency and fees, set out so that the comparison can be checked. Quoted amount, conversion…		2	40k	3mo
Compounds this community declines to help with, and why Compounds › Other compounds research use only needs a source mislabelling custom synthesis Solved Wiki Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a compound without…	+81	87	35k	10mo
A supplier who responds to a discrepancy with silence Sourcing › Red flags underdosing documentation quality moderation mislabelling Closed On the subject in the title: A supplier who responds to a discrepancy with silence Working notes rather than a conclusion. Two things I would like separated before anyone answers on supplier, because they get…		2	6.1k	16mo